Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

roxifiban

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
This investigation addressed the paradox that disintegrins and small RGD-ligands readily bind to the resting alphaIIbbeta3… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2003
2003
Thrombocytopenia is a relatively common side effect observed during glycoprotein (GP) IIb/IIIa antagonist therapy. With the oral… Expand
  • table I
  • table II
  • table III
  • figure 2
  • figure 4
2003
2003
BACKGROUND It has been expected that therapy with oral glycoprotein (GP) IIb/IIIa blockers including roxifiban will reduce… Expand
2003
2003
Roxifiban (DMP 754) is a glycoprotein (GP) IIb/IIIa antagonist. Following oral administration to humans, roxifiban is metabolized… Expand
2002
2002
Roxifiban, an experimental antithrombotic prodrug, exists as crystalline forms I and II. A quantitative solid-state nuclear… Expand
2002
2002
Roxifiban was found to exist in two polymorphic forms. The polymorphs were detected by X-ray powder diffraction and solid-state… Expand
2002
2002
Roxifiban is an ester prodrug that is hydrolyzed, after oral administration, to the active glycoprotein (GP) IIb/IIIa antagonist… Expand
2002
2002
This study was undertaken to compare the platelet binding characteristics and anti-platelet efficacy of a nonpeptide glycoprotein… Expand
Highly Cited
2000
Highly Cited
2000
In the present study, the in vitro efficacy of different platelet glycoprotein IIb/IIIa (GPIIb/IIIa) antagonists on platelet… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
1999
1999
Currently used antiplatelet drugs, including aspirin, ticlopidine, and others, are effective against certain but not all of the… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3